Last updated: February 14, 2026
Current Market Position
NDC 24208-0022 corresponds to Vitekta (elvitegravir), an integrase strand transfer inhibitor (INSTI) approved by the FDA in August 2012. It is marketed by Gilead Sciences for the treatment of HIV-1 infection, primarily in combination with other antiretroviral agents.
Market Size and Demand
The global HIV treatment market was valued at approximately $26.9 billion in 2021, with antiretroviral drugs, including integrase inhibitors, representing a significant segment. The integrase inhibitor market alone reached an estimated $10 billion in 2021, driven by increasing adoption due to favorable efficacy and tolerability profiles.
Key growth drivers include:
- Increasing HIV prevalence, particularly in Africa, Asia, and parts of Latin America.
- Advances in combination therapy regimens.
- Shifts toward once-daily, fixed-dose combinations to improve adherence.
Competitive Landscape
Main competitors include:
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
- Isentress (raltegravir)
- Dolutegravir (various formulations)
While Vitekta (elvitegravir) is less dominant than Biktarvy or Genvoya, it remains part of Gilead’s portfolio, holding a niche in treatment combinations.
Market Dynamics and Trends
- The shift from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in formulations improves safety profiles.
- Generic entry is limited; Gilead maintains exclusivity, extending market lifespan.
- Increasing adoption in low- and middle-income countries influences overall volume but limited by pricing strategies.
Regulatory and Patent Status
- Gilead’s patents for elvitegravir-related formulations expire between 2025 and 2030, indicating potential generic competition imminence.
- No recent FDA label updates or exclusivity extensions noted.
Price Analysis
Current Pricing:
- Branded formulations such as Genvoya range from $2,000 to $3,000 per month for US patients.
- Generic formulations, where available, price below $1,000 per month, though limited for elvitegravir-based products.
Pricing Trends:
- The branded price for elvitegravir-based regimens has stabilized or declined slightly over recent years due to competitive pressures.
- International prices are significantly lower, ranging from $150 to $300 per month in developing countries.
| Pricing Comparisons: |
Formulation |
US Monthly Cost |
Global Average Price |
Competitor Price Range |
| Genvoya (Gilead) |
$2,500 |
$200–$300 |
Biktarvy: ~$2,000–$2,300 |
| Biktarvy (Gilead) |
~$2,300 |
$180–$250 |
Genvoya: ~$2,500 |
| Generic elvitegravir |
~$800–$1,000 |
$150–$250 |
None widely available |
Price Projections
Short-term (1-2 years):
- Stabilization around current levels, with slight declines (~5-10%) expected due to increased generic competition.
- Launch of generic versions predicted around 2025, potentially reducing prices further, especially in the US and Europe.
Long-term (3-5 years):
- Post-expiry, generic elvitegravir could reduce prices by 50% or more.
- Market share for elvitegravir-based regimens likely declines as newer drugs (e.g., bictegravir-based formulations) gain popularity.
- Price declines in emerging markets could be steeper due to regulatory and patent challenges.
Factors Affecting Pricing and Market Share
- Patent expiration timelines.
- Entry of generics, especially from major manufacturers in India and China.
- Development of next-generation drugs with improved efficacy and safety.
- Reimbursement policies and healthcare coverage variations worldwide.
Strategic Considerations
- Gilead’s focus on combination therapies and expanding access in low-income regions will influence volume rather than price.
- Strategic pricing in licensed regions may preserve margins until patent expiry.
- Potential for biosimilar or alternative formulations to capture market share post-patent.
Summary: NDC 24208-0022, as part of Gilead’s HIV portfolio, remains relevant, though competitive pressures and patent expiration pose risks to pricing power. A gradual decline in price is projected, accelerated by generic entries starting around 2025, with prices in the US possibly falling below $1,200 per month within 3-5 years.
Key Takeaways
- The drug is part of a mature HIV treatment market valued at over $10 billion.
- Current US prices range from $2,000 to $3,000 per month; global prices are substantially lower.
- Patent expiration between 2025–2030 will likely trigger significant price reductions due to generic competition.
- Market share will shift toward newer, more tolerable regimens, reducing the dominance of elvitegravir-based formulations.
- Pricing in emerging markets will remain lower and could see further decreases following patent expiry.
FAQs
-
When are patents for NDC 24208-0022 expected to expire?
- Patents are valid until approximately 2025-2030, depending on jurisdiction and patent extensions.
-
How will generic entry impact the drug’s market share?
- Generic versions are expected post-2025, reducing prices and diminishing market share for branded formulations.
-
Are there any recent FDA label updates affecting pricing or indications?
- No significant recent updates; the drug remains indicated for HIV-1 treatment with stable usage patterns.
-
How does the drug’s efficacy compare to newer therapies?
- Efficacy is comparable, but newer drugs like bictegravir-based regimens offer improved safety profiles and convenience, influencing prescribing patterns.
-
What are the primary factors influencing price trends in the coming years?
- Patent expiry, entry of generics, development of next-generation drugs, and reimbursement policies shape future prices.
References
[1] IQVIA. "Global HIV Treatment Market Analysis," 2022.
[2] Gilead Sciences. "Vitekta (elvitegravir) Drug Label," 2012.
[3] EvaluatePharma. "Antiretroviral Drugs Market Forecast," 2022.
[4] U.S. Food & Drug Administration. "Patent and Exclusivity Data," 2022.
[5] World Health Organization. "HIV/AIDS Treatment Data," 2022.
